MiRNA-1/133a Clusters Regulate Adrenergic Control of Cardiac Repolarization

Johannes Besser¹, Daniela Malan², Katharina Wystub¹, Angela Bachmann¹, Astrid Wietelmann¹, Philipp Sasse², Bernd K. Fleischmann², Thomas Braun¹*, Thomas Boettger¹*

¹ Department of Cardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany, ² Institut für Physiologie I, Life & Brain Center, Universität Bonn, Bonn, Germany

Abstract

The electrical properties of the heart are primarily determined by the activity of ion channels and the activity of these molecules is permanently modulated and adjusted to the physiological needs by adrenergic signaling. miRNAs are known to control the expression of many proteins and to fulfill distinct functions in the mammalian heart, though the in vivo effects of miRNAs on the electrical activity of the heart are poorly characterized. The miRNAs miR-1 and miR-133a are the most abundant miRNAs of the heart and are expressed from two miR-1/133a genomic clusters. Genetic modulation of miR-1/133a cluster expression without concomitant severe disturbance of general cardiomyocyte physiology revealed that these miRNA clusters govern cardiac muscle repolarization. Reduction of miR-1/133a dosage induced a longQT phenotype in mice especially at low heart rates. Longer action potentials in cardiomyocytes are caused by modulation of the impact of β-adrenergic signaling on the activity of the depolarizing L-type calcium channel. Pharmacological intervention to attenuate β-adrenergic signaling or L-type calcium channel activity in vivo abrogated the longQT phenotype that is caused by modulation of miR-1/133a activity. Thus, we identify the miR-1/133a miRNA clusters to be important to prevent a longQT-phenotype in the mammalian heart.

Citation: Besser J, Malan D, Wystub K, Bachmann A, Wietelmann A, et al. (2014) MiRNA-1/133a Clusters Regulate Adrenergic Control of Cardiac Repolarization. PLoS ONE 9(11): e113449. doi:10.1371/journal.pone.0113449

Received July 10, 2014; Accepted October 24, 2014; Published November 21, 2014

Competing Interests: The authors have declared that no competing interests exist.

Introduction

To maintain appropriate blood flow the vertebrate heart needs to fulfill highly regulated and coordinated contraction of atria and ventricles. This process is controlled by the propagation of the electrical excitation throughout the electrical syncytium of the heart. The spreading of the excitation as well as the contractile response of the cardiomyocytes is modulated by the autonomous nervous system allowing both the adjustment of heart rate and strength of contraction. Adrenergic signaling plays a key part in the autonomous regulation and with its many downstream effectors it needs to be coordinated and highly regulated to allow the differentiated response of the heart to the needs of the physiology and to ensure the function of the heart, miRNAs control the expression of proteins at the posttranscriptional level and are therefore part of the regulatory options to control the function of such signaling networks [1]. The miRNAs miR-1 and miR-133a are the most abundant miRNAs found in the heart and these miRNAs are encoded in two clusters in the genome. The miR-1-1/133a-2 cluster on mouse chromosome 2 and the miR-1-2/133a-1 cluster on mouse chromosome 18 give rise to identical mature miR-1 or miR-133a molecules, respectively. Possible functions of the miRNAs have been addressed by different studies. For miR-1-2 a role in the regulation of cardiac conduction has been described using miR-1-2 deficient mice [2]. This model revealed that miR-1-2 might regulate protein abundance of IRX5, which represses transcription of KCND2 [3], encoding the potassium channel subunit Kv4.2 that encodes the cardiac transient outward potassium current Ito [4]. This finding has been correlated to the ECG abnormalities, namely changes in the morphology and length of the R-wave of the ECG [2]. In addition, loss of miR-1-2 caused ventricular septal defects (VSDs) with partial penetrance and this has been attributed to dysregulation of gene programs influenced by direct miR-1 targets like Hand2 [2]. Interestingly, in the recently described miR-1/1 single mutant mice an obvious phenotype with neonatal lethality, VSDs and cardiac fibrosis was only detected in a pure 129 inbreed background [5]. Here changes in several ECG-parameters were described and upregulation of Irx5 mRNA was observed, but it remains unclear, whether this causes molecular changes that might affect the electrical properties of the heart [5]. Deletion of miR-133a from the one or other genomic cluster did not cause an apparent phenotype [6]. However, complete deletion of both miR-133a copies from the genome reduced viability of newborn animals, led to increased proliferation of neonatal cardiomyocytes and ectopic expression of smooth muscle genes, an effect described to be

* Email: thomas.boettger@mpi-bn.mpg.de (TB); thomas.braun@mpi-bn.mpg.de (TB)

These authors contributed equally to this work.
mediated by the direct miR-133a target SRF [6]. Previously we have shown that the clustered miRNAs miR-1 and miR-133a act as functional units, with miR-1 negatively regulating the abundance of myocardin that in turn enhances the expression of the miR-1/133a clusters by direct transcriptional activation [7]. Thus the miR-1/133a clusters and myocardin constitute a feedback-loop and myocardin activates transcription of smooth muscle-related genes, amongst others the potassium channel Kcnmb1 that on the other hand is repressed by miR-133a. Thus these clustered miRNAs may cooperate to regulate different molecules in common biological processes. Loss of both miR-1/133a clusters is lethal at an embryonic stage earlier than E12.5 proving the function of miR-1/133a clusters in regulatory processes that are fundamental for embryonic cardiomyocyte specification. We demonstrated that this phenotype is caused to a large extent by the loss of the regulatory interaction between miR-1 and myocardin [7]. However, whereas deletion of both miR-1/133a clusters was embryonic lethal, we did not observe a major phenotype if only a single miR-1/133a cluster was deleted from the genome. On the other hand, adenoviral overexpression [8] or decreased expression of miR-1 or miR-133a in rabbit cardiomyocytes during chronic heart failure [9] have been linked to modulation of intracellular calcium release and promotion of arrhythmogenesis due to dysregulation of phosphatase activities. Thus, besides the fundamental role of miR-1/133a in development the potential relevance of the most abundant miRNAs in the heart in regulating electrophysiological properties of cardiomyocytes is still unclear to date.

We show here, that the two miR-1/133a expressing genomic clusters are involved in regulation of the impact of adrenergic signaling in cardiomyocytes and in the modulation of the electrical properties of the adult heart. Deletion of one or the other miR-1/133a cluster specifically led to longer QT intervals in the ECG. This finding is underscored at the single cell level by prolonged action potential duration and this appears to be related to altered L-type calcium-currents in cardiomyocytes. The observed longQT as well as the altered calcium-current are triggered by adrenergic signaling, indicating that the miR-1/133a clusters are essential for the maintenance of signaling pathways involved in adjustment of cardiomyocyte repolarization.

Methods

Ethics statement

All animal experiments were in accordance with German animal protection laws and were approved by the local governmental animal protection committee (Regierungpraesidium Darmstadt - Hessen, Germany; B2/272, B2/199).

Mouse models

Deletion of the miR-1-133a clusters located on mouse chromosome 2 and 18 has been described previously [7]. To further exclude possible effects of the neomycin resistance cassette used to delete the miR-1-2/133a-1 genomic region on the expression of the Mib1 gene, that contains the miR-1-2/133a-1 locus in an intron, we deleted the selection cassette using loxP sites flanking the neoR cassette. A CMV-Cre mouse [10] was used to delete the selection cassette in heterozygous miR-1-2/133a-1 mutant mice. Cre was detected by PCR (TACACTGCTGG- 

GAAGGGGACCAAA) and a WT specific primer (CATAAACACTGGCTG- 

TCCATGTGT), resulting in a 420 bp (mutant) and a 230 bp (WT) PCR product. All experiments were performed in a mixed 129/C57 background.

Histology and Immunostainings

Muscle tissues were dissected and snap frozen in Propane/Isopentane (1:2) on liquid nitrogen. Adult hearts were fixed in 4% PFA/PBS and then incubated in 30% Sucrose/PBS over night at 4°C. Tissues were embedded in Tissue Tek and cryosectioned. Sections were fixed in 4% PFA/PBS, washed 3 times with PBS and stained with DAPI and fluorophore-labeled Triticum vulgaris lectin (Sigma; L5266 or L4895; l:200). A Z1 Axioimager (Zeiss) and Imagej v1.45 was used to determine the area of muscle fibers and cardiomyocytes.

Muscle sections were fixed with 4% PFA/PBS and treated with 0.02% pepsin solution (Sigma, P6807) in 0.2 N HCl for 2 min and blocked for 45 min (2% BSA, 3% NGS, 0.5% NP-40). Anti-Myosin antibodies (Sigma, M8421, anti-skeletal-slow; 1:900 or M4276, anti-skeletal-fast; 1:500) were incubated overnight at 4°C. Biotinylated universal antibody (Vector, BA-1400) 1:1000 was applied for 2 h at room temperature. DAB-staining using the VECTASTAIN Elite ABC Kit was used to visualize fast and slow muscle fibers.

Isolation of cardiomyocytes and non-cardiomyocytes from heart

Isolation of adult mouse cardiac myocytes was done as described previously [11]. In brief, the isolated heart was cannulated via the aorta and rinsed with calcium-free perfusion buffer to remove erythrocytes. The heart was enzymatically digested by perfusion with digestion buffer until it became swollen and turned slightly pale. Atria and outflow tract were removed and the ventricle was dissociated in stop buffer. Isolated myocytes were washed and the Ca^2+ content was adjusted up to 1 mM stepwise. Cells were centrifuged twice for 1 min at 300 rpm. The cell pellet constituting the cardiomyocyte fraction was taken up in culture medium and seeded on Laminin coated dishes. Culture medium was changed after 2–3 hrs. The supernatant obtained from the centrifugation steps contains the non-cardiomyocyte fraction. Non-cardiomyocytes were collected by centrifugation for 2 min at 2000 rpm, these cells were grown on uncoated dishes in DMEM (1 g glucose, 10% FCS, 1% PSG) for 3–5 days. The culture medium of cardiomyocytes was changed after 12–16 hrs and cells were cultured overnight. For activation of the β-adrenergic signaling cardiomyocytes were washed once with cell rinse buffer (0.15 M NaCl, 40 mM Tris, 1 mM EDTA, pH 7.4) 18 h after isolation and stimulated with or w/o 1 μM Isoproterenol (I5627, Sigma) for 5 min at RT. Subsequently, supernatant was removed and SDS containing buffer added followed by immediate harvesting and sonication.

Northern blots

Total RNA from different tissues of adult mice was isolated using the Trizol method (Invitrogen). 5 μg of RNA were separated in a 15% denaturing polyacrylamide TBE-Urea gels (Invitrogen) and blotted to a Hybond-XL membrane (Amersham) that was subsequently hybridized with (γ-32P)ATP labeled miR-1 (ATA-CATACTCTTTTACATTCCA) or miR-133a (CAAGTCGTGGTGGAAAGGGGCACAAA) and U6 small RNA (ATATGAAACGGTTCAAGATTCA) probe diluted in ULTRAhyb buffer (Ambion) at 30°C overnight. The membrane was washed with SSC/SDS containing buffer and signals were detected using imaging plates.
scanned with a BAS-2500 reader (Fujifilm) and analyzed with AIDA software (v4).

**Affymetrix analysis**

Total RNA was isolated from hearts sampled at daytime (mean heart rate at daytime 480±14 bpm) from approx. 18 weeks old male mice utilizing the Trizol method (Invitrogen). RNA quality was verified using Agilent Bioanalyzer and the RNA 6000 Nano Kit. RNA was labeled following the protocol of Affymetrix. Labeled samples were hybridized to Affymetrix GeneChip Mouse 430 2.0 arrays, processed, scanned and analyzed (RMA with Affymetrix Expression console, statistical analysis using students t-test with DNASTar Arraystar 5). Microarray data are deposited at http://www.ebi.ac.uk/arrayexpress (Accession E-MTAB-2727).

**Quantitative RT-PCR**

Total RNA was isolated from tissue or cells using Invitrogen Trizol protocol. Purified RNA was reverse transcribed applying Invitrogen SuperScript II Reverse Transcription (18064-014) protocol or Applied Biosystems TaqMan MicroRNA Reverse Transcription Kit (4366596). Applied Biosystems TaqMan assays were performed following the manufacturer’s instructions using a StepOnePlus Real-Time PCR System: Acta2, Mm01204962_gH; Tgln, Mm00441661_g1; Kcnf1, Mm01215333_m1; Kcnt2, Mm01241698_g1; Gja1, Mm01179639_s1; Myocd, Mm01325105_m1; hsa-miR-1, 001973; hsa-miR-133a, 002246; U6 snRNA, 001973.

**Western blot**

Tissues or cell culture samples were homogenized and gathered in SDS containing extraction buffer, followed by sonication. Concentration was determined using the Bio-Rad DC Protein Assay for colorimetric protein concentration measurement. NuPAGE Novex 4–12% Bis-Tris Gels (Invitrogen) were loaded for 7.5–20 μg of protein. Denaturing Western blots were performed using Invitrogen NuPAGE electrophoresis protocol and solutions. Proteins were transferred to Nitrocellulose membrane and stained with Red Alert. Membranes were blocked by incubation with 5% Skim Milk Powder (70166, Fluka) in TBST and stained with Red Alert. Membranes were blocked by incubation with 5% Skim Milk Powder (70166, Fluka) in TBST, and stained with Red Alert. Membranes were blocked by incubation with 5% Skim Milk Powder (70166, Fluka) in TBST for 1 h at RT. Primary antibodies were diluted in 3% BSA or 3% milk powder in TBST and incubated overnight at 4°C. Following antibodies and dilutions were used: mouse-α-Plb Ser17 (1:50; sc-17024-R, Santa Cruz), rabbit-α-Plb Ser16 (1:50; sc-12963, Santa Cruz), rabbit-α-Calcina1c (1:200; ab58552, abcam), rabbit-α-Gapdh (1:1000; 2118, Cell Signaling Techn.), rabbit-α-Histon H3 (1/1000; 9715, Cell Signaling Techn.), rabbit-α-Prx5 (1:1000; ARP37245 P050, Aviva Systems Biology), goat-α-Kcnf1 (1:500; SC-16796, Santa Cruz), mouse-α-Myocd (1:500; MAB4028, R&D), rabbit-α-pCamKII Thr286 (1/1000; 3361, Cell Signaling Techn.), goat-α-Plb Ser16 (1:50; sc-12963, Santa Cruz), rabbit-α-Plb Thr17 (1:50; sc-17024-R, Santa Cruz), rabbit-α-pPKA C Thr197 (1/1000; 5661, Cell Signaling Techn.), rabbit-α-pTroponin I Ser23/24 (1/1000; 4004, Cell Signaling Techn.), rabbit-α-RyR2 Ser2808 (1/5000; A010-30, Badrilla), rabbit-α-RyR2 Ser2814 (1/5000; A010-31, Badrilla), rabbit-α-Sorc1n (1:500; PA5-28359, Pierce), rabbit-α-SRF (1:500; SC-335, Santa Cruz), HRP coupled secondary antibodies (goat-α-mouse, 1858413, Pierce or goat-α-rabbit, 1838415, Pierce or rabbit-α-goat, A5420 Sigma) were diluted 1:5000 in 3% Skim Milk Powder/TBST or 5% BSA/TBST and incubated for 1 h at RT. Signal detection was performed using chemiluminescence (Femto-Kit, Pierce) and a VersaDoc system (Biorad) with the software Quantity One. Signal intensity was quantified with Quantity One or ImageJ v1.45 h.

**ECG**

Surface ECG was measured using a custom made amplifier with a suitable tube to immobilize mice and electrodes positioned to the location of the paws of the mice. Amplified signals were digitized, recorded and analyzed using Powerlab and Labchart7 software (ADInstruments). For ECG analysis mouse preset settings were used, with an average time of 30 s and a maximum RT interval of 140 ms. To manipulate heart rates, mice were anesthetized after initial measurement by application of 2–2.5% Isoflurane/O₂ (20 ccm/min) to the mice. For normalization PR, QRS, QT and ST durations at different heart rates were calculated from slopes (ΔQT/ΔRR). In selected experiments 5 mg/kg Propranolol (Sigma, P0884) was applied i.p. 10 min before ECG recording. Venamul (Sigma, V4629) was administered via drinking water at a concentration of 1 g/liter [12]. Adult mice were treated for 4 weeks before measurement. Alternatively ECG of mice was recorded using TA10EA-F20 implantable telemetry transmitters (Data Sciences International). The electrodes of the transmitter were placed subcutaneously left and right on the thorax. Data were recorded every 30 min for 300 s for at least 6 days. First recordings were done 7 days after implantation of transmitter. Data were sampled with Dataquest A.R.T. 4.0 with a sample rate of 500 Hz and with a filter cut-off of 100 Hz. ECG parameters at different heart rates were obtained by different activity of the mice during day- and nighttime.

**MRI measurements**

Cardiac MRI measurements were performed on a 7.0 T Bruker Pharmascan, equipped with a 300 mT/m gradient system, using a custom-built circularly polarized birdcage resonator and the IntraGateTM self-gating tool [13]. The parameters for identification of the ECG were adapted for one heart slice and transferred afterwards to the navigator signals of the remaining slices. Thus the in-phase reconstruction of all pictures is guaranteed. MRI data were analyzed using Qmass digital imaging software (Medis). Mice were measured under volatile Isoflurane (1.5–2.0%) anesthesia. The measurement is based on the gradient echo method (repetition time = 6.2 ms; echo time = 6.0 ms; field of view = 2.20×2.20 cm; slice thickness = 1.0 mm; matrix = 128×128; repetitions = 100). The imaging plane was localized using scout images showing the 2- and 4-chamber view of the heart, followed by acquisition in short axis view, orthogonal on the septum in both scouts. Multiple contiguous short-axis slices consisting of 7 to 10 slices were acquired for complete coverage of the left and right ventricle.

**Electrophysiological recordings**

Ventricular cardiomyocytes were isolated from 30 to 36 week-old control or miR-1-1/133a-2, miR-1-2/133a-1 mice, as previously described [14]. Briefly, hearts were perfused in the Langendorff mode with Tyrode solution (135 mM NaCl, 4 mM KCl, 1 mM MgCl₂, 2.5 mM HEPES, 5 mM glucose, 25 mM butanedione monoxime; pH 7.4) for 5 min at 37°C and then with Tyrode containing 50 μM CaCl₂, 0.8 mg/ml collagenase B (Roche) and 0.3 mg/ml trypsin (Invitrogen) for 12–13 min. The ventricles were cut in small pieces and mechanically dissociated, then cells were filtered through a nylon mesh and the pellet was resuspended in Tyrode containing 50 μM CaCl₂ and 5% FCS. [Ca²⁺] in the buffer was increased in four steps from 50 μM to 1.8 mM over 40 min.

Single cells were plated at low density on laminin-coated (0.1%) coverslips in normal external solution. Patch-clamp experiments were performed using an EPC10 amplifier (Heka) in the whole cell configuration. 1.0 M NaCl was recorded in the voltage clamp mode, for recording of peak INa and recovery from inactivation of INa, the...
pipette solution contained (in mM): 3 NaCl, 133 CsCl2, 2 MgCl2, 2 NaATP, 2 TEA-Cl, 10 EGTA and 5 HEPES (pH 7.3, CsOH), the external solution: 7 NaCl, 133 CsCl2, 1.8 CaCl2, 1.2 MgCl2, 5 Hepes, 11 glucose, 0.005 nifedipine (pH 7.4, CsOH). For the recovery of inactivation kinetics peak INa was determined in response to pairs of depolarizing voltage steps from −100 mV to 10 mV with increasing delays between the two pulses (from 1.5 ms to 57 ms); for quantitation, INa amplitude of the second pulse was normalized to the first pulse, plotted against the delay and the data fitted with a mono-exponential decay. Peak INa densities were measured from the first 40 ms lasting pulse from a holding potential of −100 mV to −10 mV of the recovery from inactivation protocol. For measuring peak ICa,L, cardiomyocytes were held at a holding potential of −80 mV, then 50 ms long depolarizing voltage steps to −40 mV were applied to inactivate ICa,L, followed by 300 ms depolarizing voltage steps to +10 mV at a frequency of 0.2 Hz. For recording of IVs, depolarizing (300 ms) voltage steps from a holding potential of −90 from −40 to +50 mV in 10 mV steps (0.3 Hz) were applied. The pipette solution for the recording of ICa,L contained (in mM): 120 CsCl, 1 MgCl2, 5 Mg-ATP, 10 EGTA, and 5 Hepes (pH 7.4, CsOH). The extracellular solution was (in mM): 120 NaCl, 5 KCl, 3.6 CaCl2, 20 TEA-Cl, 1 MgCl2, and 10 Hepes (pH 7.4, TEA-OH). Stimulation and inhibition of ICa,L are reported in terms of the percentage of the increase or decrease of ICa,L density, respectively. Only cells with a variation of ICa,L density of >5% from baseline were included into the statistics.

To record the time dependent, depolarization-activated outward K+ current (IK), the cells were perfused with an external solution containing the IK blocker E4031 (1 μM), thereafter Isoproterenol (10 μM) was added and then Isoproterenol and theIKs specific blocker Chromanol (1 μM) were applied. IKs was elicited by a single 5 s lasting depolarizing voltage step to +50 mV from a holding potential of −40 mV (15). The intracellular solution for the recording of IKs contained: 140 mM KCl, 4 mM MgATP, 5 mM EGTA, 1 mM MgCl2, and 10 mM HEPES (pH 7.4, KOH). The extracellular solution contained: 140 mM N-methyl-D-glucamine, 5.4 mM KCl, 1 mM MgCl2, 0.1 mM CaCl2, 10 mM HEPES, pH 7.2, HCl. Two mM 4-aminoypyridine, 1 mM 431, 0.4 mM CdCl2, or 5 μM Nifedipine were added to block contaminating Ioff, IK, and ICa,L, respectively. All recordings were performed at room temperature.

Recording of membrane potential was performed in the current clamp mode and with a pipette solution containing (in mM): 50 KCl, 90 K-Asparatate, 1 MgCl2, 5 MgATP, 10 EGTA, 10 HEPES, pH 7.4 (KOH) and an external solution containing 140 NaCl, 5.4 KCl, 1.8 CaCl2, 1 MgCl2, 10 Hepes, 10 glucose (pH 7.4, NaOH). The same solution was used to record Action Potential (AP), which were elicited by a 2.5 ms current injection pulse of 800–1000 pA though the patch pipette. APD at 90% of repolarization was analyzed with the cardiac action potential analysis module of LabChart. Data were acquired at a sampling rate of 10-20 kHz (voltage clamp) or 5 kHz (current clamp), filtered at 1 KHz, digitized with the Patchmaster software (HEKA, Germany) and analyzed offline using the Fitmaster (HEKA) or the LabChart software (AD Instruments, USA).

Statistical analysis

Unless otherwise stated mean values with standard errors are shown. Statistical tests were performed using unpaired Student’s t-Test for all data. A p-value of <0.05 was considered significant and is indicated by * in the figures; ** corresponds to p<0.01, *** to p<0.001, ns to not significant.

Results

Knock-out of individual miR-1/133a clusters

Deletion of the miR-1-1/133a clusters from mouse chromosome 2 and 18 has been previously described [7]. Using northern blot analysis (Figure 1A) as well as qRT-PCR (Figure 1B) we demonstrate here tissue specific expression of miR-1 and miR-133a in adult heart, skeletal muscle and with reduced abundance in bladder. Isolation of cardiomyocytes and non-cardiomyocytes from cardiac tissue demonstrates that expression of both micro-RNAs is confined to cardiomyocytes (Figure 1C, n/group = 4–6). Deletion of either miR-1/133a cluster resulted in significant reduction of miR-1 or miR-133a in the adult tissues. The qRT-PCR revealed that in adult heart tissue loss of the miR-1-1/133a-2 cluster leads to a significantly stronger reduction of miR-1 than deletion of the miR-1-2/133a-1 cluster (Figure 1D, n/group = 4–6). The miR-1-2/133a-1 cluster is encoded in an intron of the protein coding gene Mib1. We found no difference in the expression of Mib1 between WT and miR-1-2/133a-1 knock-out animals (Figure S1, n/group = 2–4), deletion of the miRNA cluster from the intron of the gene did not disturb the splicing or abundance of the Mib1 mRNA.

Mice lacking a single miR-1-133a cluster develop normally and are vital

Breeding of the respective heterozygous animals in a 129/C57 mixed genetic background resulted in offspring with the expected Mendelian ratio, indicating that deletion of single miR-1-133a clusters did not cause embryonic lethality (Figure 2A). We analyzed the morphology of fetal hearts of single cluster knock-out animals at embryonic day 15.5 to screen for developmental defects (Figure 2B; n/group ≥10). We did not find changes in the histology of the heart at E15.5 and no changes in left ventricular wall or interventricular septum thickness were observed (Figure 2C, n/group ≥9). Loss of a single miR-1/133a cluster did not reduce the survival (n/group ≥97, log-rank test p>0.45) or the body weight development (n/group ≥6) of the respective knock-out animals compared to WT (Figure 2D, E). In addition, MRI analysis of heart structure and function of adult mice did not reveal obvious differences in any of the functional parameters (Figure 2F, n/group ≥7).

The miRNAs miR-1 and miR-133a are abundantly expressed in skeletal muscle. However, homozygous deletion of single miR-1/133a clusters yielded no striking changes in the morphology of skeletal muscle [7]. We did not observe alterations in fiber size distribution (Figure S2A; n/group ≥5) or changes in the number of centralized nuclei (Figure S2B). In both knock-out models we also did not observe differences in type 1 fiber content in the TA muscle (Figure S2G, D).

Loss of single miR-1-133a clusters affects repolarization of the heart in vivo

Electrocardiography was used to explore the electrophysiological consequences of loss of miR-1-133a clusters (Figure 3A). Many ECG parameters like PR- or QT-interval length strongly depend on the heart rate, thus in humans heart rate corrected parameters like the QTc are used. The algorithms used for calculation of human ECG parameters might not be appropriate for the mouse model [16], therefore ECGs were acquired at different heart rates and were analyzed dependent on heart rate or the RR interval length, respectively. ECGs were acquired using a custom made amplifier attached to a device to immobilize animals for the recording time that also allows anesthesia to manipulate the heart rate. Analysis of ECGs of our respective single miR-1-133a
cluster KO mice revealed no change in the morphology of the R wave in any of our models (Figure 3A). Also we did not observe changes in QRS complex length at different heart rates indicating that conduction and depolarization of the heart is apparently not changed (Figure 3B). No arrhythmias were detected in the ECGs of our knock-out models. However, in both KO models we consistently detected a prolonged QT interval compared to control mice of the same age and this prolongation was found to be more pronounced at lower heart rates (Figure 3B), as also indicated by statistical analysis of \( \Delta QT/\Delta RR \) (Figure 3C) for the knock-out mice (\( \Delta QT/\Delta RR \) in WT: 0.27±0.08, in miR-1-1/133a-2: 0.63±0.04 p<0.01, in miR-1-2/133a-1: 0.57±0.06 p<0.01; n = 18/10/14). Prolonged QT durations (93.0±5.0 ms at heart rate 350 bpm, \( \Delta QT/\Delta RR \); n/group 2–5, WT: 0.27±0.03, miR-1-1/133a-2: 0.57±0.02, p<0.01, miR-1-2/133a-1: 0.89±0.11, p<0.001) were also observed in miR-1-2/133a del mutant mice after deletion of the neomycin resistance cassette (n = 11), indicating that the increased QT duration always depends on the loss of miR-1/133a, but not on potential disturbance of neighboring genes. Of note the extension of the QT interval was always based on a longer ST duration with unchanged QRS duration.

In addition to ECG recordings with immobilized mice we also performed telemetric recording of ECG using implanted transmitters. Heart rates were not significantly different between WT and mutant animals with higher mean heart rates at night than at day. We took advantage of the variation of the heart rate from 400 bpm up to 650 bpm during circadian rhythm to acquire the QT interval length at different heart rates in non-sedated mice. Also in this freely moving mice we observed a significantly longer QT interval at lower heart rates in the miR-1/133a mutant mice compared to WT mice (\( \Delta QT/\Delta RR \); n/group 2–5, WT: 0.27±0.03, miR-1-1/133a-2: 0.57±0.02, p<0.01, miR-1-2/133a-1: 0.89±0.11, p<0.001). ECG data obtained by telemetric recording were screened for Torsades de pointes that potentially might occur due to prolonged QT duration. No such events were detected in more than 30 h of ECG recordings obtained from 5 different mutant mice. Although we never observed death of animals during telemetric recording of ECG, the unchanged survival of mutant knock-out animals supported the view that fatal Torsades de pointes arrhythmia did not occur in miR-1/133a KO mice.

Molecular consequences of loss of single miR-1/133a clusters

To get insights into the molecular mechanisms leading to the phenotypic changes observed after loss of single miR-1/133a clusters we analyzed transcriptional changes in WT vs. the respective miR-1/133a knock-out hearts. Microarray analysis was performed using RNA isolated from whole hearts excluding atria of 7 WT, 4 miR-1-1/133a-2 and 5 miR-1-2/133a-1 KO animals.
We only found few transcriptional changes in molecules previously described to be direct targets of miR-1 or miR-133a regulation (Table 1). In addition to unbiased transcriptome analysis we extended our analysis of mRNA expression using quantitative RT-PCR (Figure 4C, E–G, K) with higher number of independent replicates or performed western blot analysis of protein expression when applicable (Figure 4A, B, H, I, n/group = 5–9). Interestingly, we observed activation of a smooth muscle gene program in the miR-1/133a knock-out mice (Acta2, calponin, transgelin, Myl9, Myh11; table 1). In E10.5 embryonic hearts deletion of both miR-1/133a clusters resulted in upregulation of myocardin at the RNA, as well as at the protein level [7]. However, analysis of myocardin protein expression in the adult heart in contrast to protein extracts from embryonic hearts revealed signals of different molecular weight, which may be corresponding to splice variants of myocardin. None of the detected signals indicated increased protein abundance in adult heart (Figure 4A). In addition, at the protein level we observed upregulation of the miR-133a target gene SRF in the miR-1-1/133a-2 mutant mice, but not in the miR-1-2/133a-1 mutant mice (Figure 4B, D). This upregulation of SRF correlates well with the observed changes in smooth muscle genes (Table 1, Figure 4E).

Clearly, we observed upregulation of the miR-1 target gene Kcne1 in the miR-1/133a knock-out mice and confirmed that by qRT-PCR (Figure 4F). Microarray analysis detected no significant upregulation of the previously described miR-1/133a targets connexin43/Gja1, Irx5 or Cav1.2, but qRT-PCR analysis with higher n-number revealed increased abundance of connexin43 by qRT-PCR in miR-1-1/133a-2 mutant mice (Figure 4G). In contrast to previous observations we did not observe an increase of IRX5 protein abundance in either of the mouse models (Figure 4H, J). Irx5 has been suggested to be a direct transcriptional regulator of Kcnd2 and thus causal for the arrhythmias and QRS-complex malformations in the miR-1-2 knock-out mice [2], therefore we also analyzed the expression of Kcnd2 transcripts in...
our mouse models. We did not detect regulation of Kcnq2 in the microarray experiments nor by quantitative RT-PCR (Figure 4K). Cav1.2 has been described to be a miR-1 target molecule in rat and human [17]. However, the described miR-1 target sites are not conserved in the 3′UTR of mouse Cacna1c. In addition we did not detect upregulation of Cav1.2 at the protein level (Figure 4I, L) as one would predict for a miRNA target molecule after deletion of the miRNA. We detected downregulation of the CAV1.2 calcium channel that is essential for depolarization of the cardiomyocyte membrane potential during excitation, indicating secondary regulatory events.

Changes in electrophysiological properties of cardiomyocytes

To understand the cellular basis for the observed ECG changes and to identify the underlying mechanisms we performed single cell patch clamp analysis on adult isolated ventricular cardiomyocytes from both miR-1/133a cluster knock-out animals and respective littermate controls. First, we determined action potential duration at 90% of repolarization (APD$_{90}$); APs were evoked in the current clamp mode by injecting small depolarizing currents (Figure 5A). The cardiomyocytes displayed very similar resting membrane potentials (for miR-1-1/133a-2 control cells −82.2 ± 0.8 mV, n = 33, miR-1-1/133a-2 mutant cells −82.3 ± 0.8 mV, n = 39; for miR-1-2/133a-1 control cells −81.6 ± 1.3 mV, n = 31, miR-1-2/133a-1 KO cells −80.9 ± 0.9 mV, n = 29). However, we found in both miR-1-133a mutants a significantly prolonged APD$_{90}$, as would be expected from the ECG data (for miR-1-1/133a-2 control cells 21.9 ± 2.9 ms, n = 33, for miR-1-1/133a-2 KO cells 37.6 ± 1.8 ms, n = 39, p < 0.001; for miR-1-2/133a-1 control cells 23.2 ± 1.4 ms, n = 31, for miR-1-2/133a-1 KO cells 32.4 ± 2.8 ms, n = 29, p < 0.01; Figure 5B). The prolongation of the APD$_{90}$ was more pronounced in the miR-1-1/133a-2 KO cells, which was fully in agreement with the observed changes in the ECG in the respective mice. We next explored, whether prominent differences in voltage dependent ion currents could be detected by applying ramp depolarizations (from −150 to +60 mV, 250 ms). These experiments yielded similar inward and outward current components for both miR-1-133a knock-out
models and the respective control groups (Figure 5C), proving the functional expression of the most important ion currents.

One of the potential targets of the two miRNAs of interest was found to be KCNE1 [18] that together with KCNQ1 constitutes the IKs repolarizing current. We found Kcne1 upregulation in microarray experiments and qRT-PCR, however we did not detect KCNE1 protein expression in adult wildtype or miR-1/133a knock-out mouse cardiomyocytes. This is in accordance with previous reports showing that IKs and IKr are diminished in adult mouse cardiomyocytes and apparently do not play an important role for the repolarization of the cardiac AP [19], although interestingly loss of function of Kcne1 results in modulation of QT adaptation at heart rate variations in mice [16]. Moreover re-expression of a functional IKs in adult mouse cardiomyocytes would apparently favor repolarization and therefore rather cause shortening of the APD. Nevertheless, we measured the repolarizing IKs in single cardiomyocytes using well established protocols [15]. As a positive control IKs was measured in embryonic WT cardiomyocytes (E14.5–E16.5), in which IKs is known to be functionally expressed (Figure S3A–B). Then, we determined whether IKs was increased in miR-1-2/133a-1 mutant cells. Despite the observed transcriptional Kcne1 upregulation, we could not detect activation of macroscopic IKs neither in miR-1-2/133a-1 control (n = 3) nor KO cardiomyocytes (n = 13; Figure S3C, D), fully in line with the proposed lack of function of this KV component in the adult mouse heart. Thus, our data demonstrate that differences in the functional expression of IKs do not underlie the observed prolongation of the APD90.

Besides IKs, also other outwardly rectifying IK such as Ito and IKr could be responsible for the AP prolongation. Indeed the molecular basis of Ito is Kcnd2/Kv4.2 that has previously been claimed to be transcriptionally regulated by the miR-1 target Irx5 and to be at least in part responsible for cardiac conduction defects observed in miR-1-2 mutant mice [2]. That mechanism has not been confirmed in miR-1-1 mutant mice [5] and we did not see regulation of Kcnd2 transcripts in our models (Figure 4K). Nevertheless we investigated these IK components in adult cardiomyocytes in the current clamp mode without and in presence of the K+ channel blocker 4-AP (2 mM; Figure S4A–B) [19–21]. We reasoned that strong differences in the expression of these outward rectifying IK should yield drastic differences in the 4-AP effect on APD90. This was not the case (Figure S4A–B), as the 4-AP-induced prolongation of the APD90 was relatively similar in miR-1-1/133a KO cardiomyocytes compared to the respective control cardiomyocytes, indicating that the observed ECG changes are unlikely due to differences in these IK components.

Besides the expression of ion channels also changes in their modulation, in particular by hormones of the autonomous nervous system, could underlie the observed changes in the electrical features and APD prolongation. We therefore explored the effect of the adrenergic agonist Isoproterenol (1 µM) on the APs. We found that Isoproterenol application led to a clear and significant prolongation of the APD90 in all miR-1-2/133a-1 and miR-1-1/133a-2 KO cardiomyocytes (Figure 6A–C). APD90 in the miR-1-
Table 1. Transcriptome analysis after deletion of single miR-1/133a clusters.

| Fold change miR-1-1/133a-1 vs. WT | Fold change miR-1-2/133a-1 vs. WT | p-value miR-1-1/133a-1 vs. WT | p-value miR-1-2/133a-1 vs. WT | Gene symbol | Gene title | comment |
|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------|-----------|---------|
| 1.0 | 1.0 | 0.025 | 0.025 | Myh7 | myosin heavy chain I |
| 2.15 | 2.35 | 0.027 | 0.027 | Acta2 | smooth muscle alpha 2 actin |
| 2.10 | 1.68 | 0.015 | 0.003 | Myl9 | myosin regulatory light chain 9 |
| 1.84 | 1.13 | 0.005 | 0.466 | Cnn1 | calponin 1 |
| 1.67 | 0.88 | 0.023 | 0.409 | Tagln | transgelin |
| 1.64 | 0.91 | 0.003 | 0.570 | Kcne1 | K+ v-gated channel, isk-rel. subfamily, member 1 |
| 1.59 | 1.41 | 0.027 | 0.057 | Kcnd2 | K+ v-gated channel, Shal-rel. family, member 2 |
| 1.56 | 1.06 | 0.010 | 0.770 | Srf | serum response factor |
| 1.31 | 1.28 | 0.211 | 0.065 | Irx5 | Iroquois related homeobox 5 |
| 1.31 | 1.14 | 0.038 | 0.127 | Myocd | myocardin |
| 1.27 | 1.21 | 0.167 | 0.169 | Gra1 | gap junction protein, α 1 |
| 1.05 | 0.98 | 0.659 | 0.886 | Gja1 | gap junction protein, α 1 |
| 1.04 | 1.23 | 0.656 | 0.042 | Cacna1c | L-type calcium channel, α 1C subunit |
| 0.90 | 0.92 | 0.473 | 0.498 | Myh11 | myosin heavy chain 11 |

Affymetrix GeneChip transcriptome analysis after loss of single miR-1/133a clusters revealed only limited regulation of miR-1/133a target molecules. Of note Kcne1 was upregulated in both knock-out models, however many other previously described miR-1 or miR-133a targets were not regulated after loss of roughly 50% miR-1 or miR-133a. Consistent with upregulation of SRF in miR-1-1/133a-2 mutant animals we observe upregulation of smooth muscle/fetal gene program markers in these mutants. Kcnd2 has been described to be a direct transcriptional target of Irx5. The comment indicates that the gene belongs to the smooth muscle gene program (sm) or is a predicted target of miR-1/133a regulation (t).

doi:10.1371/journal.pone.0113449.t001

1/133a-2 control cardiomyocytes was 22.2±1.5 ms in normal solution and 24.1±5.6 ms (n = 18) upon Isoproterenol application, whereas in miR-1-1/133a-2 KO cardiomyocytes it increased from 35.8±2.6 ms to 42.6±3.1 ms in the presence of Isoproterenol (n = 19). Similarly, in miR-1-2/133a-1 control cells the APD90 was 16.6±1.7 ms in normal solution and 16.9±1.6 ms (n = 12), in presence of Isoproterenol, whereas in miR-1-2/133a-1 KO cells it was 26.8±2.3 ms and 35.2±4.2 ms (n = 6) in normal solution and Isoproterenol, respectively. The percentage of Isoproterenol stimulation in respect to the normal solution was for miR-1-2/133a-1 3.5±2.9% in control cells and 30.9±8.7% in KO cells (p = 0.003) and for miR-1-1/133a-2 control cells 6.5±3.1% (n = 18) and KO cells 24.2±2.5% (n = 15; p = 0.0002), respectively (Figure 6D). Since the β-adrenergic agonist Isoproterenol is involved in the modulation of the L-type calcium current (I\textsubscript{Ca,L}) and this channel is also implicated in some LQT related mutation [22,23] we next investigated the expression of this current in miR-1-1/133a-2 control and KO animals using voltage clamp protocols. Due to of the known modulation of I\textsubscript{Ca,L} by adrenergic signaling and potential differences in the phosphorylation status at rest, we analyzed I\textsubscript{Ca,L}, in IV-curves without and in presence of Isoproterenol (1 μM) (Figure 7A). The IV curves revealed a similar voltage dependence for peak I\textsubscript{Ca,L}, which was close to 0 mV (−3.0±1.5 mV and −2.9±1.8 mV, for both control and miR KO cardiomyocytes, respectively, n = 7) and shifted to a more negative potential close to −10 mV (−9.0±1.2 and −8.6±1.4 mV in control and KO cardiomyocytes, respectively, n = 7) upon Isoproterenol application. In addition, we also performed experiments, where I\textsubscript{Ca,L} density was measured at basal conditions and upon maximal stimulation by combined application of the direct adenylylate cyclase-activator Forskolin (FK, 10 μM) and the phosphodiesterase-inhibitor IBMX (100 μM) (Figure 7D). These experiments showed that I\textsubscript{Ca,L} could be stimulated either by Isoproterenol (miR-1-1/133a-2 control cells 43.4±4.2%, n = 14, miR-1-1/133a-2 KO cells 114.9±22.5%, n = 11, p = 0.012) or FK/IBMX (miR-1-1/133a-2 control cells 79.7±12.6%, n = 10, miR-1-1/133a-2 KO cells 140.2±22.1%, n = 13, p = 0.028) significantly stronger in the miR-1-1/133a-2 KO cardiomyocytes, implying differences in the phosphorylation levels (Figure 7B-C, E-F). Importantly, we did not observe significant differences in inactivation kinetics of I\textsubscript{Ca,L} between WT and KO cardiomyocytes (data not shown). Similar to the current density analysis, the analysis of the total I\textsubscript{Ca,L} charge influx showed no differences under basal conditions but upon stimulation with Isoproterenol we observed significant larger charge influx in KO cardiomyocytes compared to WT cardiomyocytes (p = 0.02, data not shown).

As reported above in the ECG evaluation, the LQT-phenotype became particularly obvious at low frequencies of the heart, which is compatible with LQT-syndromes due to alterations of voltage dependent-Na\textsuperscript{+} (LQT 3) [24] or Ca\textsuperscript{2+} (LQT 8) channels [22,23], whereas LQT-syndromes related to K\textsuperscript{+} channels (LQT1 and LQT2) become rather symptomatic at high heart rates [25,26]. Besides from I\textsubscript{Ca,L} we therefore analyzed also key electrophysiological parameters of I\textsubscript{Na}, which are known to be altered in LQT3 with a prominent prolongation of APD and life threatening arrhythmias preferentially at night albeit at low heart rates. We focused on I\textsubscript{Na} in the miR-1-2/133a-1 KO line (Figure S5A–D). The peak density of I\textsubscript{Na} in cardiomyocytes from miR-1-2/133a-1 control and KO mouse was very similar (for control cells 19.4±2.6 pA/pF, n = 13, for KO cells 17.2±2.2 pA/pF, n = 23) (Figure S5A, B). Also the recovery from inactivation of I\textsubscript{Na} was found to be in a similar range (time constant t in control cells 6.8±1.5 ms, n = 14, in KO cells 6.7±0.7 ms, n = 22) in control and KO cardiomyocytes (Figure S5C, D), indicating that typical changes of I\textsubscript{Na} as found in LQTS 3, namely reduced density of I\textsubscript{Na} and faster recovery from inactivation [24], are not responsible for the observed phenotype.

Thus, our electrophysiological evidence implies differences in the activity levels of I\textsubscript{Ca,L}, but not I\textsubscript{Na}. Defective regulation of
voltage dependent Ca\textsuperscript{2+} channels would be consistent with the observed prolongation of the APD\textsubscript{90} as well as with the increased QT-duration at low heart rates. Indeed, increased I\textsubscript{Ca,L} also led to an increased APD\textsubscript{90} in an in silico model simulating ion currents and Ca\textsuperscript{2+} fluxes of mouse ventricular cardiomyocytes (+50% I\textsubscript{Ca,L} = +41% APD\textsubscript{90}; +100% I\textsubscript{Ca,L} = +108% APD\textsubscript{90}) [27].

**Molecular analysis of adrenergic signaling**

Analysis of the electrophysiological properties of cardiomyocytes isolated from mutant mice indicated modulation in the adrenergic control of calcium channel activity upon reduced miR-1/133a expression in the single cluster mutant mice. Unbiased transcriptome analysis did not reveal prominent changes in the expression of components of the adrenergic signaling cascade that may be target of miR-1 or miR-133a regulation (Table 2). Stimulation of \(\beta\)-adrenergic receptors results in G-protein mediated activation of adenylate cyclase, subsequently cAMP formation and activation of PKA or of the calcium/calmodulin-dependent protein kinase II (CaMKII) that participates to mediate effects of \(\beta\)-adrenergic signaling on calcium handling [28]. To get insights into the activity of these cascades we first analyzed cAMP concentrations in mutant vs. WT hearts. No changes in the cAMP concentration could be detected (Figure 8A, n/group = 4–5). To reveal changes in adrenergic signaling that could potentially influence plasmamembrane calcium channel activity and hence QT duration, we isolated cardiomyocytes from WT and the respective knock-out mice and analyzed known phosphorylation target sites of the \(\beta\)-adrenergic signaling. Unfortunately, the phosphorylation the Cav1.2 calcium channel cannot reliably be accessed due to lack of appropriate antibodies. Therefore we analyzed the activation of
other cellular targets of the adrenergic signaling by comparison of Isoproterenol-stimulated vs. unstimulated cardiomyocytes isolated from WT or respective mutant mice. Isoproterenol treatment was effective to stimulate phosphorylation of known elements of the β-adrenergic signaling cascade (Figure 8B–G, n/group = 6–7). However, none of the PKA dependent phosphorylation sites analyzed (RyR S2808, Troponin S23/24, PLN S16, Figure 8C–E) occurred to be changed in its responsiveness to Isoproterenol stimulation when we compared the mutant cardiomyocytes to the respective WT controls. Interestingly the CaMKII-dependent phosphorylation of RyR2 S2814 (Figure 8F) is consistently decreased in miR-1-1/133a-2 and miR-1-2/133a-1 knock-out cardiomyocytes compared to cardiomyocytes isolated from WT mice, however the CaMKII dependent Phospholamban (PLB) T17 phosphorylation site was not differently regulated (Figure 8G). To supplement the unbiased transcriptome analysis, we analyzed protein expression of molecules potentially modifying L-type calcium channel activity (Figure S6). The analysis of protein expression confirmed our transcriptome analysis. The previously identified miR-1 target B50α was not upregulated at transcript-

Figure 6. β-adrenergic signaling prolongs APD90 in miR KO ventricular cardiomyocytes. Representative APs of control (black traces) and KO cells without (blue traces) and in presence of Isoproterenol (ISO; 1 μM, red traces) (A). Statistics of APD90 in miR WT and KO cells without and with ISO (B). Point graphs of APD90 of individual cells prior and after Isoproterenol application underscores the different response of control and miRNA KO cells (C). Percentage of increase of APD90 in miR control and KO cells (D).

doi:10.1371/journal.pone.0113449.g006
level nor on protein level and the miR-1 target Sorcin (SRI) was significantly more abundant only in miR-1-1/133a-2 mutant hearts. In addition the CAVB2 subunit of the L-type calcium channel was not differentially regulated in WT and mutant hearts. Taken together these data indicate a regulation of particular aspects of β-adrenergic signaling in miR-1/133a knock-out cardiomyocytes, may be by modulatory factors acting downstream in the adrenergic signaling cascade.

miR-1/133a regulates the impact of adrenergic signaling on L-type calcium channel activity in vivo

In vivo heart function is constantly modulated by the sympathetic and parasympathetic stimuli, thus cardiomyocytes...
are always subject to regulation by β-adrenergic signaling although to a varying degree. To demonstrate that the dysregulation of adrenergic signaling on calcium-channel activity that was observed in vitro is also the cause of the longQT observed in vivo in miR-1/133a KO mice, we investigated the effect of adrenergic signaling on ECG in WT and the respective miR-1/133a single cluster knock-out mice. Indeed, application of Propranolol and thus blockage of adrenergic signaling in vivo abrogated the longQT phenotype in miR-1/133a single cluster knock-out mice (ΔQT/DRR, p-values compared to untreated wildtype, wildtype 0.39±0.14 p>0.44, miR-1-1/133a-2 KO 0.43±0.08 p>0.32, miR-1-2/133a-1 KO 0.34±0.11 p>0.62, n = 7/4/9, Figure 9A).

In addition, direct targeting of L-type calcium-channels by Verapamil also abolished the QT duration differences between WT and the respective knock-out models (ΔQT/ΔRR, p-values compared to untreated wildtype, wildtype 0.30±0.11 p>0.85, miR-1-1/133a-2 KO 0.32±0.10 p>0.75, miR-1-2/133a-1 KO 0.35±0.14 p>0.62 n = 6/4/4; Figure 9A). Altogether these data support the notion that dysregulation of L-type calcium channel activity by disturbed impact of β-adrenergic signaling is the cause of LQT in mice with reduced expression of miR-1/133a (Figure 9B).

Discussion

Our analysis of single miR-1-133a clusters in a mixed 129/C57 genetic background indicated that the single miR-1-133a clusters are not essential for early development and structural integrity of the heart. However, reduction of miR-1-133a abundance in the single cluster knock-out mice revealed other important physiological functions of these miRNAs. Our thorough analysis of ECG parameters uncovered that the miR-1-133a clusters are needed to maintain specific functions in heart electrophysiology and modulation of miR-1-133a dosage caused a striking change in the frequency dependent modulation of QT duration leading to long QT disease phenotype that becomes particularly evident at lower heart rates.
LQT in miR-1/133a mutant mice is caused by unleashed β-adrenergic control of L-type calcium channel

QT duration is primarily regulated by the function of ion channels and these ion channels are modulated by changes in the activity of interacting molecules and it becomes increasingly clear that the interaction of many components finally determines the electrophysiological properties of the heart [29]. This tight regulation of QT-duration is essential for general heart function to prevent potentially fatal arrhythmias and on the other hand these properties have to be fine-tuned to the functional requirements of a species. Deletion of a single miR-1/133a cluster led to longQT and this was corroborated by significantly prolonged APD90 duration at the single cell level. However, our detailed analysis of the electrophysiological properties of isolated cardiomyocytes from both miR-1/133a knock-out models did not reveal

Table 2. Potential miR-1/133a targets involved in modulation of adrenergic signaling.

| Fold change miR-1-1/133a-2 vs. WT | Fold change miR-1-2/133a-1 vs. WT | p-value miR-1-1/133a-2 vs. WT | p-value miR-1-2/133a-1 vs. WT | Gene symbol | Gene title | predicted target of miRNA |
|----------------------------------|----------------------------------|-------------------------------|-------------------------------|-------------|-----------------|--------------------------|
| 1.07                             | 1.03                             | 0.460                         | 0.411                         | Adcy1       | adenylylate cyclase 1 | miR-133a (ts) |
| 1.12                             | 0.98                             | 0.006                         | 0.701                         | Adcy5       | adenylylate cyclase 5 | miR-133a (ts) |
| 1.07                             | 1.03                             | 0.605                         | 0.683                         | Adcy6       | adenylylate cyclase 6 | miR-133a (ts) |
| 1.14                             | 0.94                             | 0.167                         | 0.457                         | Adcy7       | adenylylate cyclase 7 | miR-133a (ts) |
| 1.17                             | 0.99                             | 0.143                         | 0.945                         | Adora1      | adenosine A1 receptor | miR-133a (ts) |
| 0.99                             | 0.96                             | 0.919                         | 0.620                         | Adra1a      | adrenergic receptor, α 1a | miR-133a (ts) |
| 0.98                             | 1.11                             | 0.846                         | 0.254                         | Adra1b      | adrenergic receptor, α 1b | miR-1 (ts) |
| 1.03                             | 0.96                             | 0.479                         | 0.432                         | Adra2a      | adrenergic receptor, α 2a | miR-133a (ts) |
| 0.93                             | 0.89                             | 0.610                         | 0.177                         | Adrbk2      | adrenergic receptor kinase, beta 2 | miR-1 (ts) |
| 1.11                             | 1.14                             | 0.244                         | 0.118                         | Akap12      | A kinase (PRKA) anchor protein (gravin) 12 | miR-133a (ts, m) |
| 1.11                             | 1.08                             | 0.142                         | 0.249                         | Akap13      | A kinase (PRKA) anchor protein 13 | miR-1 (ts) |
| 1.17                             | 1.05                             | 0.096                         | 0.459                         | Akap2       | A kinase (PRKA) anchor protein 2 | miR-1 (ts) |
| 1.12                             | 1.01                             | 0.095                         | 0.876                         | Akap5       | A kinase (PRKA) anchor protein 5 | miR-133a (ts) |
| 1.03                             | 1.04                             | 0.698                         | 0.506                         | Akap8       | A kinase (PRKA) anchor protein 8 | miR-133a (ts) |
| 1.05                             | 1.04                             | 0.203                         | 0.463                         | Akap9       | A kinase (PRKA) anchor protein (yotiao) 9 | miR-133a (ts) |
| 1.01                             | 1.05                             | 0.925                         | 0.493                         | Atp2a2      | Ca-ATPase, cardiac muscle, slow twitch 2 | miR-133a (ts) |
| 0.97                             | 1.07                             | 0.684                         | 0.452                         | Calm2       | calmodulin 2 | miR-1 (ts) |
| 1.09                             | 1.03                             | 0.415                         | 0.566                         | Camk2a      | Ca/calmodulin-dependent protein kinase II α | miR-1 (m) |
| 0.72                             | 0.77                             | 0.029                         | 0.162                         | Camk2d      | Ca/calmodulin-dependent protein kinase II, delta | miR-133a (ts) |
| 1.02                             | 1.12                             | 0.812                         | 0.056                         | Gna1        | guanine nucleotide binding protein, γ inhibiting 1 | miR-133a (ts) |
| 1.02                             | 1.02                             | 0.705                         | 0.470                         | Gna3        | guanine nucleotide binding protein, γ inhibiting 3 | miR-133a (ts) |
| 1.23                             | 1.16                             | 0.071                         | 0.064                         | Gnb1        | guanine nucleotide binding protein, beta 1 | miR-1 (ts) |
| 1.05                             | 1.02                             | 0.339                         | 0.774                         | Gng12       | guanine nucleotide binding protein, γ 12 | miR-1 (ts) |
| 1.02                             | 1.00                             | 0.833                         | 0.988                         | Gng4        | guanine nucleotide binding protein, γ 4 | miR-1/133a (m) |
| 1.08                             | 1.12                             | 0.092                         | 0.062                         | Gng7        | guanine nucleotide binding protein, γ 7 | miR-1 (ts) |
| 1.04                             | 1.04                             | 0.379                         | 0.375                         | Pde4b       | phosphodiesterase 4B, cAMP specific | miR-1 (ts, m) |
| 0.98                             | 0.99                             | 0.659                         | 0.687                         | Pde6a       | phosphodiesterase 6A, cGMP-specific, rod, γ | miR-133a (ts) |
| 0.77                             | 0.75                             | 0.045                         | 0.017                         | Pde7a       | phosphodiesterase 7A | miR-1 (ts, m) |
| 1.02                             | 1.05                             | 0.797                         | 0.224                         | Pde8b       | phosphodiesterase 8B | miR-1 (ts, m) |
| 1.06                             | 0.89                             | 0.559                         | 0.091                         | Pla2g4a      | phospholipase A2, group IVA | miR-1 (ts, m) |
| 1.12                             | 1.02                             | 0.190                         | 0.751                         | Plcb2       | phospholipase C, β 2 | miR-133a (ts) |
| 1.08                             | 1.08                             | 0.318                         | 0.374                         | Ppp2ca      | protein phosphatase 2, catalytic subunit, α isofom | miR-133a (ts) |
| 1.14                             | 1.05                             | 0.272                         | 0.367                         | Ppp2ra5a    | protein phosphatase 2, regulatory subunit B (B56), α | miR-1 (ts) |
| 0.94                             | 1.01                             | 0.603                         | 0.854                         | Prkaa2      | protein kinase, AMP-activated, α2 catalytic subunit | miR-1 (ts, m) |
| 1.09                             | 1.17                             | 0.178                         | 0.006                         | Prkacb      | protein kinase, cAMP dependent, catalytic, β | miR-1 (ts) |
| 1.21                             | 1.03                             | 0.183                         | 0.792                         | Sdc8a1      | solute carrier family 8, member 1 | miR-1 (ts) |
| 1.22                             | 1.00                             | 0.031                         | 0.988                         | Sri         | sorcin | miR-1 (ts, m) |

Molecules known to be involved in adrenergic signaling as well as functionally related molecules were analyzed for potential targeting by mmu-miR-1 or mmu-miR-133a using Targetscan (ts) and mirBase.org (m) and transcriptional regulation of these molecules was analyzed. Of the 177 molecules analyzed to be related to adrenergic signaling 39 were predicted potential targets of miR-1 or miR-133a. doi:10.1371/journal.pone.0113449.t002
striking alterations of potassium and sodium current expression and function. Instead, we detected an increased L-type calcium channel activity. This became visible when we mimicked the tonic adrenergic stimulation of the cardiomyocytes that naturally occurs in the intact heart. Increased L-type calcium channel activity has been identified to be responsible for the LQT8 observed in human Timothy’s syndrome and the influence of β-adrenergic signaling on this ion-channel and on long QT is well known. Enhanced L-type calcium channel activity could lead to prolonged APD either by longer and stronger depolarization during the plateau phase of APs or by enhanced Ca^{2+} flux through the channel. The larger amount of Ca^{2+} subsequently needs to be exported by the electrogenic Na^{+}-Ca^{2+} exchanger which leads to inward currents and delayed (after-) depolarization upon Ca^{2+} removal. Thus also altered intracellular Ca^{2+} buffering in KO cardiomyocytes could enhance the effects of enhanced L_{Ca,L} on the Na^{+}-Ca^{2+} exchanger and APD prolongation. In contrast to loss-of-function mutation in LQT1 patients which leads to prolonged QT durations and induction of ventricular tachycardia at higher heart rates [30] in the miR-1/133a mutant mouse models we have detected the opposite effect on QT/RR slope, namely prolongation of action potential duration at lower heart rates. This is very similar to the situation reported in LQT3 patients [31] and mice [24] due to a gain of function mutation of the voltage dependent Na^{+} channel, that shows the most prominent effect at slow heart rates. We believe that the miR-1/133a KO - induced gain of function effects on the Ca^{2+} currents after β-adrenergic stimulation is similarly leading to prolonged QT durations at slow heart rate. This is

Figure 9. miR-1/133a controls impact of β-adrenergic regulation on L-type calcium-channel. The increased slope of ΔQT/ΔRR indicates LQT at low heart rates in miR-1-1/133a-2 and miR-1-2/133a-1 mutant mice. The LQT was rescued in vivo by inhibition of β-adrenergic signaling using Propranolol or by inhibition of L-type calcium channel using Verapamil, respectively (A). This result confirms the in vitro measurements proving that the miR-1/133a clusters modulate β-adrenergic signaling mediated regulation of L-type calcium channel activity and that loss of this modulation causes LQTS after deletion of single miR-1/133a clusters. Thus the miR-1/133a clusters are essential for repression of the smooth muscle gene program in post-natal heart and for maintenance of repolarization properties that are essential for normal function of the heart in its physiological context (B).

doi:10.1371/journal.pone.0113449.g009
supported by the fact that both the β-blocker Propranolol as well as the Ca^{2+}-channel blocker verapamil attenuates the miR-1/133a KO - induced effects on the QT/RR slope in vivo (Figure 9A).

Although Cacna1c, coding for Cav1.2 protein, which is the α-subunit of the L-type calcium channel was suggested to be a miR-1 target in humans [17], we could not confirm direct regulation of Cav1.2 protein abundance by miR-1 in mouse cardiomyocytes, obviously because the miR-1 binding sites are not sufficiently conserved in mouse Cacna1c. We even observed a decrease in protein abundance for the Cav1.2 α-subunit of the L-type calcium channel in our models, arguing for secondary effects but not for release from miRNA mediated repression in the mutant animals.

The activity of the L-type calcium channel is modulated by modification and interacting molecules [32,33]. We therefore assumed that other, probably β-adrenergic signaling dependent mechanisms might cause an increased L-type calcium channel current in isolated cardiomyocytes. To understand the molecular mechanisms, how miR-1/133a might cause the changed L-type calcium channel activity, we analyzed adrenergic signaling in cardiomyocytes isolated from WT and the respective miR-1/133a knock-out cardiomyocytes. Although several components of the adrenergic signaling cascade are potential direct targets of repression by miR-1 or miR-133a no particularly significant change in the abundance of these molecules in vivo or in isolated cardiomyocytes was detected. This was different compared to a recent study using transgenic overexpression of miR-133 [34], but in line with our data that showed that there is no hypertrophic growth after loss of single miR-1/133a clusters [7] that could potentially be attributed to increased adrenergic signaling [20]. Thus we functionally analyzed the adrenergic signaling cascade further downstream by determination of the phosphorylation status of several of its components with and without adrenergic stimulation. For several of the known components of this signaling we did not detect differences in phosphorylation at baseline or after adrenergic stimulation compared to WT controls. Of note, no changes in well-known targets of PKA mediated β-adrenergic signaling were observed. Interestingly, there is a significant change in the CaMKII dependent RyR2 Ser2021 phosphorylation at baseline and after stimulation confirming that miR-1/133a directly or indirectly affects β-adrenergic signaling of miR-1/133a mutant cardiomyocytes. RyR2 Ser2021 has been identified to be regulated by PP2A regulatory subunit B56α that is a candidate miR-1 target gene [0,9]. However, the B56α subunit was not regulated in cardiomyocytes with reduced miR-1/133a expression. Moreover, reduced CaMKII signaling should reduce activity of the L-type calcium channel [35], thus this change cannot be accounted for the increased L-type calcium channel activity seen in the miR-1/133a single cluster mutant cells. Our unbiased analysis of transcriptional changes after mutation of single miR-1/133a clusters revealed the miR-1 target Sorcin [36] to be significantly upregulated at least in miR-1-1/133a-2 knock-out mice and we could confirm this finding at the protein level. Whereas it is established that Sorcin may enhance contractility of cardiomyocytes, it is currently unclear whether Sorcin might also modulate L-type calcium channel activity in vivo [37]. We found moderate upregulation of Sorcin only in one of the models. Thus we exclude Sorcin to be the cause of longQT in both models. Taken together, although we did not identify a single miR-1 or miR-133a target molecule responsible for the modulation of adrenergic signaling in our models, numerous molecules related to this pathway are potential targets of miR-1/133a regulation. We suggest that the sum of subtle changes governed by miR-1/133a regulates the impact of adrenergic signaling on L-type calcium channel activity and thus caused LQT in the models with reduced miR-1/133a expression.

**Mutation of single miR-1/133a clusters reveal molecular targets modulated by physiological levels of miRNA regulation in cardiomyocytes**

The deletion of the single miR-1-1/133a clusters offers the opportunity to modulate the miR-1/133a dosage in a way that closely matches the physiological relevant regulation. In vivo transcriptional regulation of miR-1/133a clusters would affect both miRNAs within the cluster, and modulation of miRNA abundance without complete loss of expression occurs also in pathophysiological settings [38].

Reduction of miR-1 to approximately 70% (miR-1-1/133a mutants) or 40% (miR-1-1/133a-2 mutants) and concomitant miR-133a reduction revealed gradual regulation of several previously described miR-1/133a targets like Kcnq1 [18] and connexin43 [39] and SRF [6]. However, the observed regulation of Kcnq1 and connexin43 did not have obvious functional consequences. Nevertheless, the regulatory interaction between miR-1 and Kcnq1 might be of more importance in humans and indicates that Kcnq1 might be added to a miR-1/133a regulated network of genes that modulates repolarization of cardiomyocytes. Increased abundance of IRX5 protein after loss of miR-1-2 [2] and of IRX3 mRNA after loss of miR-1-1 [5] has been reported. Our analysis revealed that Irx5 protein expression was not increased in the hearts of the mouse mutants described here. In accordance with this, we also did not see regulation of the putative IRX5 downstream gene Kcnd2 that has been observed in the miR-1-2 mutants, moreover we did not observe the QRS complex abnormalities or arrhythmogenesis that were at least in part attributed to the dysregulation of a IRX5-Kcnd2 axis [2].

miR-1/133a controls expression of smooth muscle genes in cardiomyocytes

Deletion of miR-1-1/133a-2 revealed a moderate but significant increase of SRP protein in mutant cardiomyocytes, whereas this increase was not significant in miR-1-2/133a-1 mutant cardiomyocytes. The miR-1 target myocardin, that is a SRF interacting transcriptional coactivator, was found to be increased after deletion of both miR-1-1/133a clusters in embryonic heart [7] or after complete deletion of both miR-1 copies in neonatal heart [5], but was not significantly upregulated in the adult single cluster mutant cardiomyocytes. These results demonstrate that the regulatory power of miRNA strongly depend on the actual changes in miRNA abundance.

Although the miR-133a target SRF was increased in miR-133a double mutant hearts [6], it was not increased in embryonic hearts after complete deletion of miR-1/133a [7], indicating that there are also developmental stage specific components modulating miRNA mediated regulation of target protein abundance. Hereby, our analysis supports the view that only careful consideration of experimental miRNA levels in the specific physiological back-ground is useful to reveal physiological functions of miRNAs. Indeed only after more than 50% reduction of mature miR-1 and miR-133a we observed a moderate impact on SRF expression and concomitant increase of several smooth muscle markers in the adult heart. However, in the more severely affected miR-1-1/133a-2 model we observed no considerable impact on functional parameters of the heart under physiological conditions.

In summary, we suggest that modulation of components of adrenergic signaling regulating the action potential duration of cardiomyocytes might be subject to complex regulation by miR-1-
and miR-133a. In line with the common models of miRNA action the longQT phenotype after loss of a single miR-1-1/133a cluster seems not to be caused by dysregulation of a single ion-channel or a single ion-channel interacting protein, thus we suggest that the miR-1-1/133a cluster fine-tune different components of the adrenergic signaling to the needs of physiological function in vivo. Indeed the rescue of the long QT-phenotype either by inhibition of the adrenergic signaling or by Verapamil-induced modulation of L-type calcium channel activity in vivo indicates that the miRNAs miR-1 and miR-133a modulate an important functional property of the heart (Figure 9). In other vertebrates this impact might be developed differently. KCNQ1 for instance has a prominent role in repolarization in humans or Cav1.2 as a part of L-type calcium-channel is regulated by miR-1 due to functional miR-1 binding sites in humans. Therefore we suggest that miR-1-1/133a clusters participate in fine-tuning the regulation of cardiac repolarization according to the needs of the different species. A more profound understanding of the miRNA-mediated mechanisms regulating QT duration may help to develop appropriate therapeutic strategies to prevent the potentially fatal arrhythmias.

Supporting Information

Figure S1 Deletion of the intronic miR-1-2/133a-1 cluster does not affect the expression of the host gene Mib1. RT-PCR using oligonucleotides directed against exons flanking the miR-1-2/133a-1 containing intron (A) indicates that splicing of the Mib1 gene is not disturbed (B) despite deletion of the miR-1-2/133a-1 encoding region of the Mib1 intron. (C) qRT-PCR indicates that also the abundance of Mib1 mRNA is unchanged in the miR-1-2/133a-1 knockout-out mice described here. (TIF)

Figure S2 Loss of miR-1-133a single clusters does not impair muscle structure. Histological analysis of muscle structure did not reveal changes in TA muscle of single cluster mutant mice compared to WT. (A) Fiber size distribution and (B) number of centralized nuclei was not changed. (C, D) Type 1 fiber staining indicates no change in fiber type distribution. Comparable regions of TA muscle stained for slow myosin (Sigma) are depicted in D. The scale bar corresponds to 100 μm. (TIF)

Figure S3 Macroscopic IKs is not detected in adult control and miR-1-2/133a-1 KO ventricular cardiomyocytes, but in control embryonic cardiomyocytes. Representative voltage clamp recordings in wildtype embryonic (E14.5–16.5) (A, B) and in control (C) and miR-1-2/133a-1 knock-out (D) adult cardiomyocytes to detect IKs: the three different voltage recordings were performed in presence of a selective blocker of IKr (1 μM E4031; 1 black), of Isoproterenol (1 μM ISO; 2 red), and of Isoproterenol and a selective IKs blocker (1 μM Chromanol; 3 blue). Note the slowly activating outward current in the embryonic cardiomyocyte after Isoproterenol application, which could be blocked by Chromanol indicative for IKs, whereas this IK component could not be detected in control and miR-1-2/133a-1 KO adult ventricular cardiomyocytes. The time course of peak IK of the cardiomyocytes shown in B is displayed in A, IKs was elicited by 5 s long depolarizing voltage steps to +50 mV, followed by a step to 0 mV, holding potential –40 mV, rate 0.05 Hz. (TIF)

Figure S4 The IK blocker 4-Aminopyridine (4-AP) has similar effects in control and miR-1-1/133a-2 KO ventricular cardiomyocytes. AP recordings in respective miR control (left) and KO cells in normal solution (NS, black and blue traces) and after application of 4-AP (2 mM, red traces). (B) APD90 for miR-1-1/133a-2 (left panel) and miR-1-2/133a-1 control and KO cells (right panel). (C) % of increase of the APD90 in control and KO cells upon application of 4-AP (APD90 prolongation in presence of 4-AP for miR-1-1/133a-2 control cells 208.5±31.6, n = 14, for miR-1-1/133a-2 KO cells, 158.3±30.5, n = 13; for miR-1-2/133a-1 control cells 80.9±10.1%, n = 10, for miR-1-2/133a-1 KO cells, 54.1±11.1%, n = 14). (TIF)

Figure S5 INa is similar in miR-1-2/133a-1 control and KO ventricular cardiomyocytes. Representative INa traces recorded from miR-1-2/133a-1 control (A, left) and KO (A, right) ventricular cardiomyocytes in response to 40 ms lasting depolarizing pulses from –80 mV to –10 mV in 10 mV intervals, holding potential –100 mV. The depicted traces were recorded at –10 mV. (B) Statistics of peak INa density at the step potential of –10 mV in both groups of cells. (C) Representative analysis of recovery from inactivation of peak INa measured at 2 mM extracellular Na+. INa amplitude was normalized with the first voltage step to –10 mV, holding potential –100 mV. (D) Statistical analysis of the exponential fit of the recovery from inactivation kinetics of INa. (TIF)

Figure S6 Molecules affecting L-type calcium channel activity. Western blot analysis reveals unchanged expression of the potential miR-1 targets B36x (A) and a significant increase in protein abundance of Sorcin (SRI) in miR-1-1/133a-2 mutant hearts (B). The abundance of the L-type calcium channel beta subunit CAVβ2 is not changed (C). (TIF)

Acknowledgments

The authors thank Sylvia Thomas, Marion Wiesnet, Ursula Hofmann, Frank Holst and Susanne Kreutzer for technical support of this work.

Author Contributions

Conceived and designed the experiments: JB PS BKF T. Braun T. Boettger. Performed the experiments: JB DM KW AW PS T. Boettger. Analyzed the data: JB DM KW AB PS T. Boettger. Wrote the paper: JB PS BKF T. Braun T. Boettger.

References

1. Boettger T, Braun T (2012) A new level of complexity: the role of microRNAs in cardiovascular development. Circulation research 110: 1000–1013.
2. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, et al. (2007) Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129: 303–317.
3. Costantini DL, Arruda EP, Agarwal P, Kim KH, Zhu Y, et al. (2005) The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell 123: 347–358.
4. Guo W, Jung WE, Marionneau C, Amond F, Xu H, et al. (2005) Targeted deletion of Kv4.2 eliminates Eko& and results in electrical and molecular remodeling, with no evidence of ventricular hypertrophy or myocardial dysfunction. Circ Res 97: 1342–1350.
5. Heidersbach A, Sadyh Y, Carver-Moore K, Huang Y, Ang YS, et al. (2013) microRNA-1 regulates sarcomere formation and suppresses smooth muscle gene expression in the mammalian heart. Nature 503: 1432–1433.
6. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, et al. (2008) microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22: 3242–3254.
7. Wüstuh K, Basler J, Bachmann A, Boettger T, Braun T (2013) miR-1/133a clusters cooperatively specify the cardiomyogenic lineage by adjustment of
myocardin levels during embryonic heart development. PLoS Genet 9: e1003793.

8. Terentyev D, Belevych AE, Terentyeva R, Martin MM, Malana GE, et al. (2009) miR-1 overexpression enhances Ca2+ release and promotes cardiac arrhythmogenesis by targeting P2PA regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circulation research 104: 514–521.

9. Belevych AE, Sansom SE, Terentyeva R, Ho HT, Nishijima Y, et al. (2011) MicroRNA1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 6: e28324.

10. Su H, Mills AA, Wang X, Bradley A (2002) A targeted X-linked CMV-Cre line.

11. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ (1996) Developmental involvement of IsK-associated K+ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. Circulation research 83: 95–102.

12. O’Connell TD, Rodrigo MC, Simpson PC (2007) Isolation and culture of adult mouse cardiac myocytes. Methods Mol Biol 357: 271–296.

13. Morris SA, Weiss LM, Factor S, Bilezikjian JP, Tanowitz H, et al. (1989) Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol 14: 782–789.

14. Larson AG, White RD, Laub G, McVeigh ER, Li D, et al. (2004) Self-gated cardiac cine MRI. Magn Reson Med 51: 93–102.

15. Knollmann BC, Casimiro MC, Katchman AN, Sirekno SG, Schober T, et al. (2004) Isoproterenol exacerbates a long QT phenotype in Kcnq1-deficient neonatal mice: possible roles for human-like Kcnq1 isoform 1 and slow delayed rectifier K+ current. J Pharmacol Exp Ther 310: 311–318.

16. Drici MD, Arrighi I, Chouabe C, Mann JR, Lazdunski M, et al. (1998) MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 6: e28324.

17. Rau F, Freyermuth F, Bilezikjian JP, Tanowitz H, et al. (1989) Verapamil ameliorates clinical, pathologic and biochemical manifestations of experimental chagasic cardiomyopathy in mice. J Am Coll Cardiol 14: 782–789.

18. Jia XM, Zheng SH, Xie XX, Zhang YJ, Wang WZ, et al. (2013) MicroRNA-1 and -133 increase arrhythmogenesis in heart failure by dissociating phosphatase activity from RyR2 complex. PLoS One 6: e28324.

19. Wang L, Feng ZP, Kondo CS, Sheldon RS, Duff HJ (1996) Developmental involvement of IsK-associated K+ channel in heart rate control of repolarization in a murine engineered model of Jervell and Lange-Nielsen syndrome. Circulation research 83: 95–102.

20. Ridley JM, Milnes JT, Zhang YH, Wichtel HJ, Hancox JC (2003) Inhibition of Ca2+ release from RyR2 controls the beta1-adrenergic receptor transduction cascade. Circ Res. 102: 838–844.

21. Harveys RD, Hove JW (2013) CAV1.2 signaling complexes in the heart. J Mol Cell Cardiol 52: 143–152.

22. Nuyens D, Brokken JL, Sipkema P, Groenboer A, Ploegh TH, et al. (2009) The genetic basis of long QT and short QT syndromes: a mutation update. Human mutation 30: 1496–1511.

23. Takenaka K, Ati T, Shimizu W, Kobori A, Nominoya T, et al. (2003) Exercise stress test amplifies genotype-phenotype correlation in the LQTF1 and LQTF2 forms of the long-QT syndrome. Circulation 107: 838–844.

24. Holmén F, Flockerzi V, Kahn S, Wengener JW (2014) L-type CaV1.2 calcium channels: from in vitro findings to in vivo function. Physiol Rev 94: 303–326.

25. Castaldi A, Zaglia T, De Mauro V, Carullo P, Viggiani G, et al. (2014) MiR-133 Modulates the beta1-Adrenergic Receptor Transduction Cascade. Circ Res.

26. Fischer TH, Neef S, Maier LS (2013) The Ca-calmodulin dependent kinase II: a promising target for future antiarrhythmic therapies? J Mol Cell Cardiol 58: 182–187.

27. Ali R, Huang Y, Maher SE, Kim RW, Giordano FJ, et al. (2012) miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling. J Mol Cell Cardiol 52: 1027–1037.

28. Fouquer MR, Colotti G, Ghiami E, Hugiu C, Seidler T, et al. (2009) Complex modulation of L-type Ca2+ current inactivation by Sorcin in isolated rabbit cardiomyocytes. Pflugers Arch 457: 1049–1060.

29. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, et al. (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13: 613–618.